Pain and Physical Function Improvements TRIUMPH-4's co-primary endpoint focused on knee osteoarthritis pain, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale: WOMAC Pain Score Reductions: Retatrutide 9mg: -4.5 points (75.8% reduction) Retatrutide 12mg: -4.4 points (73.3% reduction) Placebo: -2.4 points (40.3% reduction) Participants also experienced substantial improvements in physical function, with WOMAC physical function subscale scores improving by: Retatrutide 9mg: -4.1 points Retatrutide 12mg: -4.2 points Placebo: -2.1 points Perhaps most remarkably, a post-hoc analysis revealed that 14.1% of participants on 9mg and 12.0% on 12mg became completely pain-free at 68 weeks, compared to just 4.2% on placebo
The Critical Link: GH and IGF-1 Now we get to the heart of the matter
R.KneislJ
The excess amount of blood aldehyde produce facial flushing, nausea, rapid heartbeat, and other adverse effects
View The Five Stocks Here The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation
